BR112018067995A2 - composição oftalmológica - Google Patents

composição oftalmológica

Info

Publication number
BR112018067995A2
BR112018067995A2 BR112018067995A BR112018067995A BR112018067995A2 BR 112018067995 A2 BR112018067995 A2 BR 112018067995A2 BR 112018067995 A BR112018067995 A BR 112018067995A BR 112018067995 A BR112018067995 A BR 112018067995A BR 112018067995 A2 BR112018067995 A2 BR 112018067995A2
Authority
BR
Brazil
Prior art keywords
hyaluronic acid
ophthalmic composition
composition
ectoin
ophthalmologically
Prior art date
Application number
BR112018067995A
Other languages
English (en)
Other versions
BR112018067995B1 (pt
Inventor
Holzer Frank
Warda Isabella
Mahler Markus
Steinfeld Ute
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58264510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018067995(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Publication of BR112018067995A2 publication Critical patent/BR112018067995A2/pt
Publication of BR112018067995B1 publication Critical patent/BR112018067995B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção se refere a uma composição oftalmológica com alta viscosidade. a composição de acordo com a invenção contém ou consiste, neste caso, em ácido hialurônico ou em um derivado de ácido hialurônico, tal como, por exemplo, em um sal oftalmologicamente aceitável do ácido hialurônico, assim como em ectoína ou um derivado de ectoína oftalmologicamente aceitável. além disso, a composição é caracterizada pelo fato de que não compreende qualquer outra substância constitutiva farmaceuticamente eficaz.
BR112018067995-0A 2016-03-07 2017-03-07 Composição oftalmológica BR112018067995B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102016203696.3 2016-03-07
DE102016203696.3A DE102016203696A1 (de) 2016-03-07 2016-03-07 Ophthalmologische Zusammensetzung
PCT/EP2017/055338 WO2017153415A1 (de) 2016-03-07 2017-03-07 Ophthalmologische zusammensetzung

Publications (2)

Publication Number Publication Date
BR112018067995A2 true BR112018067995A2 (pt) 2019-01-15
BR112018067995B1 BR112018067995B1 (pt) 2023-09-26

Family

ID=58264510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067995-0A BR112018067995B1 (pt) 2016-03-07 2017-03-07 Composição oftalmológica

Country Status (15)

Country Link
US (1) US20190099441A1 (pt)
EP (1) EP3426226B1 (pt)
JP (1) JP2019511494A (pt)
KR (1) KR20180117635A (pt)
CN (1) CN108778250A (pt)
AU (1) AU2017231697B2 (pt)
BR (1) BR112018067995B1 (pt)
CA (1) CA3015592A1 (pt)
DE (1) DE102016203696A1 (pt)
ES (1) ES2922821T3 (pt)
LT (1) LT3426226T (pt)
MX (1) MX2018010788A (pt)
PT (1) PT3426226T (pt)
RU (1) RU2749723C2 (pt)
WO (1) WO2017153415A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016203696A1 (de) 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung
EP3852725A4 (en) * 2018-09-20 2022-08-03 The Hong Kong University of Science and Technology EYE DROP COMPOSITIONS
CN109771427A (zh) * 2019-01-30 2019-05-21 上海克琴科技有限公司 一种通过提高依克多因光学纯度来增强其安全性和抗炎抗过敏活性的方法
EP3827818A1 (en) * 2019-11-26 2021-06-02 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
CN110974830A (zh) * 2019-12-26 2020-04-10 华熙生物科技股份有限公司 一种用于预防、缓解或治疗皮肤过敏的外用组合物及其用途
CN111518627A (zh) * 2020-05-09 2020-08-11 华熙生物科技股份有限公司 一种隐形眼镜护理液以及制备方法
CN111467349B (zh) * 2020-05-14 2021-06-01 华熙生物科技股份有限公司 人工泪液及其制备方法
CN111407774B (zh) * 2020-05-15 2022-03-22 华熙生物科技股份有限公司 一种眼科用组合物及其制备方法
CN111905094B (zh) * 2020-06-15 2022-08-09 华熙生物科技股份有限公司 一种眼用组合物及其在制备用于干眼症的药物中的用途
CN112220102B (zh) * 2020-09-25 2022-12-09 山东华熙海御生物医药有限公司 一种含透明质酸和依克多因的电子烟液及其制备方法
CN112480483B (zh) * 2020-11-27 2022-02-01 华熙生物科技股份有限公司 一种依克多因-透明质酸复合凝胶的制备方法及所得产品
CN112870455B (zh) * 2021-02-05 2022-05-24 华熙生物科技股份有限公司 一种含透明质酸的凝胶制剂、制法及其在内窥镜检查中的应用
US12012238B2 (en) * 2021-05-26 2024-06-18 Bausch + Lomb Ireland Limited Packaging solutions
CN116139067B (zh) * 2021-11-22 2024-03-22 华熙生物科技股份有限公司 透明质酸锌形成凝胶的方法及含有透明质酸锌的滴眼凝胶及其制备
CN114569491B (zh) * 2022-04-18 2023-08-18 华熙生物科技股份有限公司 一种抑制油脂生成的组合物及其用途
CN116024050A (zh) * 2022-12-14 2023-04-28 江苏视准医疗器械有限公司 一种角膜接触镜保存液组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4342560A1 (de) 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
JP4540872B2 (ja) * 2001-04-02 2010-09-08 株式会社資生堂 乾燥による皮膚傷害の抑制剤もしくは修復剤
DE10161149B4 (de) 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
US7160560B2 (en) * 2003-10-23 2007-01-09 L'oreal S.A. Skin-care composition
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
CN101491526A (zh) * 2009-03-03 2009-07-29 山东大学 四氢嘧啶在制备治疗关节炎的药物中的应用
DE102014007423A1 (de) 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
DE102016203696A1 (de) 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung

Also Published As

Publication number Publication date
CN108778250A (zh) 2018-11-09
KR20180117635A (ko) 2018-10-29
MX2018010788A (es) 2019-01-14
BR112018067995B1 (pt) 2023-09-26
PT3426226T (pt) 2022-07-20
CA3015592A1 (en) 2017-09-14
ES2922821T3 (es) 2022-09-20
RU2018130713A (ru) 2020-04-08
US20190099441A1 (en) 2019-04-04
WO2017153415A1 (de) 2017-09-14
LT3426226T (lt) 2022-07-25
DE102016203696A1 (de) 2017-09-07
AU2017231697A1 (en) 2018-09-13
EP3426226A1 (de) 2019-01-16
AU2017231697B2 (en) 2022-07-07
EP3426226B1 (de) 2022-05-04
RU2749723C2 (ru) 2021-06-16
RU2018130713A3 (pt) 2020-06-30
JP2019511494A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
BR112018067995A2 (pt) composição oftalmológica
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
CO2017011851A2 (es) Compuestos novedosos
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
DOP2016000195A (es) Compuestos
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
MX2017007299A (es) Composiciones en suspension de liberacion prolongada gastroretentivas.
DOP2017000213A (es) Derivados de bencimidazol como inhibidores de bromodominio
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
BR112018068341A2 (pt) 6-hidróxi-4-oxo-1,4-di-hidropirimidina-5-carboxamidas como agonistas de apj
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CR20180352A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
BR112018003864A2 (pt) método para preparação de uma composição de ácido hialurônico, composição, e, método para restauração de um tecido
BR112016021282A8 (pt) processos para a preparação de compostos antifúngicos e os referidos compostos
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
TW201613603A (en) Pharmaceutical preparation
MX2018016290A (es) Agente antidesgaste.
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
BR112016022749A2 (pt) compostos de azole substituído por amido como inibidores de tnks1 e/ou tnks2
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
BR112018010644A2 (pt) método para melhorar a liberação de ar de um óleo lubrificante

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2017, OBSERVADAS AS CONDICOES LEGAIS